Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States.
Department of Pharmacy, Mayo Clinic, Rochester, MN, United States.
Heart Lung. 2021 Mar-Apr;50(2):173-176. doi: 10.1016/j.hrtlng.2020.11.003. Epub 2020 Nov 24.
Vasoplegic syndrome occurs in 8% to 12% of cases that use cardiopulmonary bypass and carries a high mortality. Although the precise cause of this shock state has yet to determined, it is postulated to be related to abnormal nitric oxide (NO)-mediated dilatation of vascular smooth muscle resulting in arterial and venous vasodilatation. Since its first report in 2014, the off-label use of hydroxocobalmin as a rescue therapy for the treatment of refractory vasodilatory shock has gained attention with a mechanism thought to be primarily mediated by the scavenge, binding to, and prevention of the formation of NO. Importantly, no dose-finding study of hydroxocobalamin for the treatment of vasoplegic shock has been published. Consequently, dosing is extrapolated from the treatment of cyanide toxicity (5 g administered by intravenous infusion over 15 min) and the hemodynamic improvement only appears to persist for a few hours when administered as a bolus. Herein we describe twelve patients with vasoplegic shock following cardiac surgery that received an extended duration infusion of hydroxocobalamin administered over a median of 6 h and illustrate the rapidity and durability of the hemodynamic response encountered.
血管麻痹综合征发生在使用体外循环的病例中占 8% 至 12%,死亡率很高。尽管这种休克状态的确切原因尚未确定,但据推测与异常一氧化氮 (NO) 介导的血管平滑肌扩张有关,导致动脉和静脉扩张。自 2014 年首次报告以来,羟钴胺素被超适应证用作难治性血管扩张性休克治疗的抢救疗法引起了关注,其作用机制主要被认为是通过清除、结合和防止一氧化氮的形成来介导的。重要的是,尚无羟钴胺素治疗血管麻痹性休克的剂量确定研究。因此,剂量是从氰化物毒性的治疗中推断出来的(5g 通过静脉输注在 15 分钟内给药),并且当作为推注给药时,仅在几小时内似乎持续存在血流动力学改善。在此,我们描述了 12 例心脏手术后发生血管麻痹性休克的患者,他们接受了羟钴胺素的延长时间输注,中位时间为 6 小时,并说明了遇到的血流动力学反应的快速性和持久性。